These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 21704105)

  • 21. New combination vaccines: DTaP-IPV (Kinrix) and DTaP-IPV/Hib (Pentacel).
    Johns TL; Hutter GE
    Ann Pharmacother; 2010 Mar; 44(3):515-23. PubMed ID: 20197476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A combined Haemophilus influenzae type B Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when coadministered with diphtheria, tetanus, acellular pertussis hepatitis B-inactivated poliovirus at 3, 5 and 11 months of age: results of an open, randomized, controlled study.
    Vesikari T; Forstén A; Desole MG; Ferrera G; Caubet M; Mesaros N; Boutriau D
    Pediatr Infect Dis J; 2013 May; 32(5):521-9. PubMed ID: 23190785
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibody persistence after a primary series of a new DTaP-IPV-Hep B-PRP-T combined vaccine or separate DTaP-IPV//PRP-T and hepatitis B vaccines at 2, 4, and 6 months of age and the effect of a subsequent DTaP-IPV//PRP-T booster vaccination at 18 months of age in healthy Argentinean infants.
    Tregnaghi M; Zambrano B; Santos-Lima E
    Pediatr Infect Dis J; 2012 Jan; 31(1):e24-30. PubMed ID: 22157567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2-7 months of age.
    Scheifele DW; Halperin SA; Smith B; Ochnio J; Meloff K; Duarte-Monteiro D
    Vaccine; 2006 Mar; 24(12):2057-64. PubMed ID: 16356598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
    Halperin SA; Tapiero B; Law B; Diaz-Mitoma F; Duval B; Langley JM; Elrick DB; Jacquet JM
    Vaccine; 2006 May; 24(18):4017-23. PubMed ID: 16516357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
    Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age: a phase III, modified double-blind, randomized, controlled, multicenter study.
    Berner R; Boisnard F; Thomas S; Mwawasi G; Reynolds D
    Vaccine; 2012 Jul; 30(35):5270-7. PubMed ID: 22691430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does concomitant injection of a combined diphtheria-tetanus-acellular pertussis - hepatitis B virus - inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccines?
    Usonis V; Bakasenas V
    Eur J Pediatr; 1999 May; 158(5):398-402. PubMed ID: 10333123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.
    Esposito S; Tansey S; Thompson A; Razmpour A; Liang J; Jones TR; Ferrera G; Maida A; Bona G; Sabatini C; Pugni L; Emini EA; Gruber WC; Scott DA; Principi N
    Clin Vaccine Immunol; 2010 Jun; 17(6):1017-26. PubMed ID: 20427630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS; Phua KB; Lee BW; Quak SH; Teoh YL; Ramakrishnan G; Han HH; Van Der Meeren O; Jacquets JM; Bock HL
    Southeast Asian J Trop Med Public Health; 2011 Jan; 42(1):138-47. PubMed ID: 21323176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
    Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
    Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children.
    Halperin SA; Langley JM; Hesley TM; Zappacosta PS; Radley D; Smith B; Hoffenbach A; Boslego J; Silber JL
    Hum Vaccin; 2005; 1(6):245-50. PubMed ID: 17012871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H; Black S; Thear M; Coury D; Reisinger K; Rothstein E; Xu J; Hartzel J; Evans B; Digilio L; Schödel F; Brown ML; Kuter B;
    Pediatr Infect Dis J; 2006 Apr; 25(4):287-92. PubMed ID: 16567978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
    Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine.
    Lin TY; Wang YH; Huang YC; Chiu CH; Lin PY; Chen CJ; Chavand P; Ortiz E
    Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
    Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
    J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.